Please use this identifier to cite or link to this item: http://dx.doi.org/10.25673/110465
Title: Heart failure and cardiorenal syndrome : a narrative review on pathophysiology, diagnostic and therapeutic regimens : from a cardiologist’s view
Author(s): Mitsas, Angelos C.
Elzawawi, Mohamed
Mavrogeni, Sophie
Boekels, Michael
Khan, Asim
Eldawy, Mahmoud
Stamatakis, Ioannis
Kouris, Dimitrios
Daboul, Baraa
Gunkel, OliverLook up in the Integrated Authority File of the German National Library
Bigalke, BorisLook up in the Integrated Authority File of the German National Library
Gisteren, Ludger
Almaghrabi, SaifalislamLook up in the Integrated Authority File of the German National Library
Noutsias, MichelLook up in the Integrated Authority File of the German National Library
Issue Date: 2022
Type: Article
Language: English
Abstract: In cardiorenal syndrome (CRS), heart failure and renal failure are pathophysiologically closely intertwined by the reciprocal relationship between cardiac and renal injury. Type 1 CRS is most common and associated with acute heart failure. A preexistent chronic kidney disease (CKD) is common and contributes to acute kidney injury (AKI) in CRS type 1 patients (acute cardiorenal syndrome). The remaining CRS types are found in patients with chronic heart failure (type 2), acute and chronic kidney diseases (types 3 and 4), and systemic diseases that affect both the heart and the kidney (type 5). Establishing the diagnosis of CRS requires various tools based on the type of CRS, including non-invasive imaging modalities such as TTE, CT, and MRI, adjuvant volume measurement techniques, invasive hemodynamic monitoring, and biomarkers. Albuminuria and Cystatin C (CysC) are biomarkers of glomerular filtration and integrity in CRS and have a prognostic impact. Comprehensive “all-in-one” magnetic resonance imaging (MRI) approaches, including cardiac magnetic resonance imaging (CMR) combined with functional MRI of the kidneys and with brain MRI are proposed for CRS. Hospitalizations due to CRS and mortality are high. Timely diagnosis and initiation of effective adequate therapy, as well as multidisciplinary care, are pertinent for the improvement of quality of life and survival. In addition to the standard pharmacological heart failure medication, including SGLT2 inhibitors (SGLT2i), renal aspects must be strongly considered in the context of CRS, including control of the volume overload (diuretics) with special caution on diuretic resistance. Devices involved in the improvement of myocardial function (e.g., cardiac resynchronization treatment in left bundle branch block, mechanical circulatory support in advanced heart failure) have also shown beneficial effects on renal function.
URI: https://opendata.uni-halle.de//handle/1981185920/112420
http://dx.doi.org/10.25673/110465
Open Access: Open access publication
License: (CC BY 4.0) Creative Commons Attribution 4.0(CC BY 4.0) Creative Commons Attribution 4.0
Journal Title: Journal of Clinical Medicine
Publisher: MDPI
Publisher Place: Basel
Volume: 11
Issue: 23
Original Publication: 10.3390/jcm11237041
Page Start: 1
Page End: 19
Appears in Collections:Open Access Publikationen der MLU

Files in This Item:
File Description SizeFormat 
jcm-11-07041-v2.pdf2.14 MBAdobe PDFThumbnail
View/Open